FSGS

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-586.4K ExitQ1 2026 $586k -- $30.95
Ken GriffinCitadel Advisors $586k19.3k shares ExitQ4 2025 $1.1M $30.43 $30.95
Ken GriffinCitadel Advisors $586k19.3k shares TrimQ4 2025 $516k $30.43 $30.95
Ken GriffinCitadel Advisors $125.2K AddQ3 2025 $125k -- $30.95
Ken GriffinCitadel Advisors $125.2K AddQ3 2025 $125k -- $30.95
Ken GriffinCitadel Advisors $588.2K AddQ2 2025 $588k -- $30.95

News

gurufocus.comEverest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversiongurufocus.comJun 4

gurufocus.comTravere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseasesgurufocus.comJun 2

Trade FSGS

About First Trust SMID Growth Strength ETF

The First Trust SMID Growth Strength ETF (the "Fund") aims to deliver investment performance that broadly matches the price movements and income generation (before accounting for the Fund's own fees and expenses) of an equity benchmark, specifically The SMID Growth Strength Index (the "Index"). Ordinarily, the Fund will allocate a minimum of 80% of its net assets (which may include funds borrowed for investment purposes) to the securities that constitute this Index.

IPO Date: Jun 26, 2017

Market Data

Open: $30.88
High: $30.96
Low: $30.83
Volume: 3.6K
Avg Volume: 2.9K
52W High: $32.08
52W Low: $28.35

Valuation

Market Cap: $28M
Dividend Yield: 39.3%

Financials

Financial statement snapshot is not available yet.

Events

DividendDec 13

$0.3931